The FDA approves Merck’s (NYSE:MRK) Keytruda (pembrolizumab) as monotherapy for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy (bladder removal).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.